Glucocorticoid resistance as a major drive in sepsis pathology

Cytokine and Growth Factor Reviews

Volumn 35, Issue , 2017, Pages 85-96

  Dendoncker, Karen ^a,b   Libert, Claude ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Glucocorticoid resistance; Inflammation; Metabolism; Sepsis

Indexed keywords

CORTICOSTERONE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR BETA; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 4; HYDROCORTISONE; INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LACTIC ACID; LIVER X RECEPTOR; METHYLPREDNISOLONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PREDNISOLONE; PYRUVATE DEHYDROGENASE KINASE 4; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BINDING AFFINITY; CATABOLISM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOWN REGULATION; GENE EXPRESSION; GENETIC REGULATION; GENETIC TRANSCRIPTION; GLUCONEOGENESIS; HUMAN; LOW DRUG DOSE; NITRATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG RESISTANCE; INFLAMMATION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; MICE; RECEPTORS, GLUCOCORTICOID; SEPSIS; SIGNAL TRANSDUCTION;

EID: 85018985478     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2017.04.002     Document Type: Review

References (216)

1. Hench, P.S., Kendall, E.C., The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis, Proceedings of the staff meetings. Mayo Clin. 24:8 (1949), 181–197.
2. Annane, D., The role of ACTH and corticosteroids for sepsis and septic shock: an update. Front. Endocrinol., 7, 2016, 70.
3. Chadda, K., Annane, D., The use of corticosteroids in severe sepsis and acute respiratory distress syndrome. Ann. Med. 34:7–8 (2002), 582–589.
4. Milligan, N.M., Newcombe, R., Compston, D.A., A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: clinical effects. J. Neurol. Neurosurg. Psychiatry 50:5 (1987), 511–516.
5. Barnes, P.J., Molecular mechanisms of corticosteroids in allergic diseases. Allergy 56:10 (2001), 928–936.
6. Overman, R.A., Yeh, J.-Y.Y., Deal, C.L., Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. 65:2 (2013), 294–298.
7. Galon, J., Franchimont, D., Hiroi, N., Frey, G., Boettner, A., Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J., 2002.
8. Martin, G.S., Mannino, D.M., Eaton, S., The epidemiology of sepsis in the United Statesfrom 1979 through 2000. N. Engl. J. Med., 2003.
9. Cowan, S.L., Holland, J.A.A., Kane, A.D., Frost, I., Boyle, A.A., The burden of sepsis in the Emergency Department: an observational snapshot. Eur. J. Emerg. Med. 22:5 (2015), 363–365.
10. Ward, P.A., Bosmann, M., A historical perspective on sepsis. Am. J. Pathol. 181:1 (2012), 2–7.
11. Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M.R., Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:7 (2001), 1303–1310.
12. Wang, H.E., Shapiro, N.I., Angus, D.C., Yealy, D.M., National estimates of severe sepsis in United States emergency departments. Crit. Care Med. 35:8 (2007), 1928–1936.
13. Garber, G., Gibney, R.N., Light, B., Martin, C., Cunningham, K., Guimond, J.-G.G., Magder, S., Russell, J., Guidance on patient identification and administration of recombinant human activated protein C for the treatment of severe sepsis. Can. J. Infect. Dis. 13:6 (2002), 361–372.
14. Mormede, P., Foury, A., Barat, P., Corcuff, J.-B.B., Terenina, E., Marissal-Arvy, N., Moisan, M.-P.P., Molecular genetics of hypothalamic-pituitary-adrenal axis activity and function. Ann. N. Y. Acad. Sci. 1220 (2011), 127–136.
15. Calogero, A.E., Bagdy, G., Szemeredi, K., Tartaglia, M.E., Gold, P.W., Chrousos, G.P., Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology 126:4 (1990), 1888–1894.
16. Häusler, A., Monnet, G., Peter, O., Involvement of GABAB receptors in the regulation of the hypothalamo-pituitary-adrenocortical (HPA) axis in rats. J. Steroid Biochem. Mol. Biol. 46:6 (1993), 767–771.
17. Navarra, P., Tsagarakis, S., Faria, M.S., Rees, L.H., Besser, G.M., Grossman, A.B., Interleukins-1 and −6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology 128:1 (1991), 37–44.
18. Besedovsky, H.O., del Rey, A., Klusman, I., Furukawa, H., Monge Arditi, G., Kabiersch, A., Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. J. Steroid Biochem. Mol. Biol. 40:4–6 (1991), 613–618.
19. Miller, W.L., Auchus, R.J., The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32:1 (2011), 81–151.
20. Walker, J.J., Spiga, F., Gupta, R., Rapid intra-adrenal feedback regulation of glucocorticoid synthesis. J. R. Soc. Interface, 12(102), 2015 20140875.
21. Breuner, C.W., Orchinik, M., Plasma binding proteins as mediators of corticosteroid action in vertebrates. J. Endocrinol. 175:1 (2002), 99–112.
22. Tomlinson, J.W., Walker, E.A., Bujalska, I.J., 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25:5 (2004), 831–866.
23. Beato, M., Klug, J., Steroid hormone receptors: an update. Hum. Reprod. Update 6:3 (2000), 225–236.
24. Boumpas, D.T., Chrousos, G.P., Wilder, R.L., Cupps, T.R., Balow, J.E., Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. 119:12 (1993), 1198–1208.
25. Schmid, W., Cole, T.J., Blendy, J.A., Schütz, G., Molecular genetic analysis of glucocorticoid signalling in development. J. Steroid Biochem. Mol. Biol. 53:1–6 (1995), 33–35.
26. Lopes da Silva, S., Burbach, J.P., The nuclear hormone-receptor family in the brain: classics and orphans. Trends Neurosci. 18:12 (1995), 542–548.
27. Bockmühl, Y., Murgatroyd, C.A., Kuczynska, A., Adcock, I.M., Almeida, O.F., Spengler, D., Differential regulation and function of 5'-untranslated GR-exon 1 transcripts. Mol. Endocrinol. (Baltimore, Md.) 25:7 (2011), 1100–1110.
28. Oakley, R.H., Cidlowski, J.A., Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J. Biol. Chem. 286:5 (2011), 3177–3184.
29. Bamberger, C.M., Bamberger, A.M., de Castro, M., Chrousos, G.P., Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J. Clin. Invest. 95:6 (1995), 2435–2441.
30. Kino, T., Su, Y.A., Chrousos, G.P., Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Cell. Mol. Life Sci.: CMLS 66:21 (2009), 3435–3448.
31. Schaaf, M.J.M., Cidlowski, J.A., AUUUA motifs in the 3′UTR of human glucocorticoid receptor α and β mRNA destabilize mRNA and decrease receptor protein expression. Steroids 67:7 (2002), 627–636.
32. Vreugdenhil, E., Verissimo, C.S.L., Mariman, R., Kamphorst, J.T., Barbosa, J.S., Zweers, T., Champagne, D.L., Schouten, T., Meijer, O.C., de Kloet, R.E., Fitzsimons, C.P., MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology 150:5 (2009), 2220–2228.
33. Li, J.J., Tay, H.L., Maltby, S., Xiang, Y., Eyers, F., Hatchwell, L., Zhou, H., Toop, H.D., Morris, J.C., Nair, P., Mattes, J., Foster, P.S., Yang, M., MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity. J. Allergy Clin. Immunol. 136:2 (2015), 462–473.
34. Kim, R.Y., Horvat, J.C., Pinkerton, J.W., Starkey, M.R., Essilfie, A.T., Mayall, J.R., Nair, P.M., Hansbro, N.G., Jones, B., Haw, T.J., Sunkara, K.P., Nguyen, T.H., Jarnicki, A.G., Keely, S., Mattes, J., Adcock, I.M., Foster, P.S., Hansbro, P.M., MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2. J. Allergy Clin. Immunol. 139:2 (2017), 519–532.
35. Riester, A., Issler, O., Spyroglou, A., Rodrig, S.H., Chen, A., Beuschlein, F., ACTH-dependent regulation of microRNA as endogenous modulators of glucocorticoid receptor expression in the adrenal gland. Endocrinology 153:1 (2012), 212–222.
36. Lu, N.Z., Cidlowski, J.A., Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol. Cell, 2005.
37. Duma, D., Jewell, C.M., Cidlowski, J.A., Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol. 102:1–5 (2006), 11–21.
38. Anbalagan, M., Huderson, B., Murphy, L., Rowan, B.G., Post-translational modifications of nuclear receptors and human disease. Nucl. Recept Signal., 10, 2012.
39. Nicolaides, N.C., Galata, Z., Kino, T., Chrousos, G.P., Charmandari, E., The human glucocorticoid receptor: molecular basis of biologic function. Steroids 75:1 (2009), 1–12.
40. Vandevyver, S., Dejager, L., Libert, C., Comprehensive overview of the structure and regulation of the glucocorticoid receptor. Endocr. Rev. 35:4 (2014), 671–693.
41. Zhang, S., Liang, X., Danielsen, M., Role of the C terminus of the glucocorticoid receptor in hormone binding and agonist/antagonist discrimination. Mol. Endocrinol. 10:1 (1996), 24–34.
42. Dong, D.D., Jewell, C.M., Bienstock, R.J., Cidlowski, J.A., Functional analysis of the LXXLL motifs of the human glucocorticoid receptor: association with altered ligand affinity. J. Steroid Biochem. Mol. Biol. 101:2–3 (2006), 106–117.
43. Grad, I., Picard, D., The glucocorticoid responses are shaped by molecular chaperones, The glucocorticoid responses are shaped by molecular chaperones. Mol. Cell. Endocrinol. 275 (2007), 2–12 (1-2).
44. Pratt, W.B., Toft, D.O., Steroid receptor interactions with heat shock protein and immunophilin chaperones 1. Endocr. Rev. 18:3 (1997), 306–360.
45. Vandevyver, L., On the trail of the glucocorticoid receptor: into the nucleus and back. Traffic (Copenhagen, Denmark) 13:3 (2012), 364–374.
46. Lim, H.-W.W., Uhlenhaut, N.H., Rauch, A., Weiner, J., Hübner, S., Hübner, N., Won, K.-J.J., Lazar, M.A., Tuckermann, J., Steger, D.J., Genomic redistribution of GR monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo. Genome Res. 25:6 (2015), 836–844.
47. Hudson, W.H., Youn, C., Ortlund, E.A., Crystal structure of the mineralocorticoid receptor DNA binding domain in complex with DNA. PLoS One, 9(9), 2014.
48. Reddy, T.E., Pauli, F., Sprouse, R.O., Neff, N.F., Newberry, K.M., Garabedian, M.J., Myers, R.M., Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res. 19:12 (2009), 2163–2171.
49. John, S., Sabo, P.J., Thurman, R.E., Sung, M.-H., Biddie, S.C., Johnson, T.A., Hager, G.L., Stamatoyannopoulos, J.A., Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. 43:3 (2011), 264–268.
50. Grøntved, L., John, S., Baek, S., Liu, Y., Buckley, J.R., Vinson, C., Aguilera, G., Hager, G.L., C/EBP maintains chromatin accessibility in liver and facilitates glucocorticoid receptor recruitment to steroid response elements. EMBO J. 32:11 (2013), 1568–1583.
51. Burd, C.J., Ward, J.M., Crusselle-Davis, V.J., Kissling, G.E., Phadke, D., Shah, R.R., Archer, T.K., Analysis of chromatin dynamics during glucocorticoid receptor activation. Mol. Cell. Biol. 32:10 (2012), 1805–1817.
52. Burd, C.J., Archer, T.K., Chromatin architecture defines the glucocorticoid response. Mol. Cell. Endocrinol. 380:1 (2013), 25–31.
53. Thomas-Chollier, M., Watson, L.C., Cooper, S.B., Pufall, M.A., Liu, J.S., Borzym, K., Vingron, M., Yamamoto, K.R., Meijsing, S.H., A naturally occurring insertion of a single amino acid rewires transcriptional regulation by glucocorticoid receptor isoforms. Proc. Natl. Acad. Sci. U. S. A. 110:44 (2013), 17826–17831.
54. Darimont, B.D., Wagner, R.L., Apriletti, J.W., Stallcup, M.R., Kushner, P.J., Baxter, J.D., Fletterick, R.J., Yamamoto, K.R., Structure and specificity of nuclear receptor-coactivator interactions. Genes. Dev. 12:21 (1998), 3343–3356.
55. Cho, S., Blackford, J.A., Simons, S.S., Role of activation function domain-1, DNA binding, and coactivator GRIP1 in the expression of partial agonist activity of glucocorticoid receptor-antagonist complexes. Biochemistry 44:9 (2005), 3547–3561.
56. Jenkins, B.D., Pullen, C.B., Darimont, B.D., Novel glucocorticoid receptor coactivator effector mechanisms. Trends Endocrinol. Metab. 12:3 (2001), 122–126.
57. Li, G., Heaton, J.H., Gelehrter, T.D., Role of steroid receptor coactivators in glucocorticoid and transforming growth factor beta regulation of plasminogen activator inhibitor gene expression. Mol. Endocrinol. (Baltimore, Md.) 20:5 (2006), 1025–1034.
58. Stashi, E., Lanz, R.B., Mao, J., Michailidis, G., Zhu, B., Kettner, N.M., Putluri, N., Reineke, E.L., Reineke, L.C., Dasgupta, S., Dean, A., Stevenson, C.R., Sivasubramanian, N., Sreekumar, A., Demayo, F., York, B., Fu, L., O'Malley, B.W., SRC-2 is an essential coactivator for orchestrating metabolism and circadian rhythm. Cell Rep. 6:4 (2014), 633–645.
59. Mahajan, M.A., Samuels, H.H., A new family of nuclear receptor coregulators that integrate nuclear receptor signaling through CREB-binding protein. Mol. Cell. Biol. 20:14 (2000), 5048–5063.
60. Surjit, M., Ganti, K., Mukherji, A., Ye, T., Hua, G., Metzger, D., Li, M., Chambon, P., Widespread negative response elements mediate direct repression by agonist- liganded glucocorticoid receptor. Cell, 145(2), 2010.
61. Kassel, O., Herrlich, P., Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol. Cell. Endocrinol., 275(1-2), 2007.
62. Ratman, D., Vanden Berghe, W., Dejager, L., Libert, C., Tavernier, J., Beck, I.M., De Bosscher, K., How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol. Cell. Endocrinol. 380:1-2 (2013), 41–54.
63. Lin, H.-Y.Y., Why we need to revise the definition and diagnostic criteria for sepsis. Chin. J. Traumatol. 18:5 (2015), 249–250.
64. Marshall, J.C., Sepsis-3. What is the meaning of a definition?. Crit. Care Med. 44:8 (2016), 1459–1460.
65. Rocha, C.M., Corrêa, A.J., de Assunção, M.S., Silva, E., Current concepts on hemodynamic support and therapy in septic shock. Braz. J. Anesthesiol. (Elsevier) 65:5 (2015), 395–402.
66. Marshall, J.C., Sepsis: rethinking the approach to clinical research. J. Leukoc. Biol. 83:3 (2008), 471–482.
67. Vincent, J.-L.L., Sun, Q., Dubois, M.-J.J., Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34:8 (2002), 1084–1093.
68. Angus, D.C., van der Poll, T., Severe sepsis and septic shock. N. Engl. J. Med. 369:21 (2013), 2062–2063.
69. Abraham, E., Anzueto, A., Gutierrez, G., Tessler, S., San Pedro, G., Wunderink, R., Dal Nogare, A., Nasraway, S., Berman, S., Cooney, R., Levy, H., Baughman, R., Rumbak, M., Light, R.B., Poole, L., Allred, R., Constant, J., Pennington, J., Porter, S., Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet (London, England) 351:9107 (1998), 929–933.
70. Jedynak, M., Siemiątkowski, A., Rygasiewicz, K., Molecular basics of sepsis developement. Anaesthesiol. Intens. Ther. 44:4 (2012), 221–225.
71. Papathanassoglou, E.D., Giannakopoulou, M.D., Bozas, E., Genomic variations and susceptibility to sepsis. AACN Adv. Crit. Care 17:4 (2006), 394–422.
72. Yadav, H., Cartin-Ceba, R., Balance between hyperinflammation and immunosuppression in sepsis. Semin. Respir. Crit. Care Med. 37:1 (2016), 42–50.
73. Rice, T.W., Wheeler, A.P., Morris, P.E., Paz, H.L., Russell, J.A., Edens, T.R., Bernard, G.R., Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit. Care Med. 34:9 (2006), 2271–2281.
74. Qiu, P., Cui, X., Barochia, A., Li, Y., Natanson, C., Eichacker, P.Q., The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opin. Investig. Drugs 20:11 (2011), 1555–1564.
75. Shakoory, B., Carcillo, J.A., Chatham, W.W., Amdur, R.L., Zhao, H., Dinarello, C.A., Cron, R.Q., Opal, S.M., Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit. Care Med. 44:2 (2016), 275–281.
76. Levi, M., van der Poll, T., Coagulation and sepsis. Thromb. Res. 149 (2017), 38–44.
77. Ward, P.A., In sepsis, complement is alive and well. Crit. Care Med. 44:5 (2016), 1026–1027.
78. Charchaflieh, J., Rushbrook, J., Worah, S., Zhang, M., Activated complement factors as disease markers for sepsis. Dis. Markers, 2015, 2015, 382463.
79. Papaioannou, V.E., Chouvarda, I.G., Maglaveras, N.K., Pneumatikos, I.A., Temperature variability analysis using wavelets and multiscale entropy in patients with systemic inflammatory response syndrome, sepsis, and septic shock. Crit. Care (London, England), 16(2), 2012.
80. Granger, J.I., Ratti, P.-L.L., Datta, S.C., Raymond, R.M., Opp, M.R., Sepsis-induced morbidity in mice: effects on body temperature, body weight, cage activity, social behavior and cytokines in brain. Psychoneuroendocrinology 38:7 (2013), 1047–1057.
81. Plummer, M.P., Deane, A.M., Dysglycemia and glucose control during sepsis. Clin. Chest Med. 37:2 (2016), 309–319.
82. Arts, R.J., Gresnigt, M.S., Joosten, L.A., Netea, M.G., Cellular metabolism of myeloid cells in sepsis. J. Leukoc. Biol. 101:1 (2017), 151–164.
83. Preechasuk, L., Suwansaksri, N., Ipichart, N., Vannasaeng, S., Permpikul, C., Sriwijitkamol, A., Hyperglycemia and glycemic variability are associated with the severity of sepsis in nondiabetic subjects. J. Crit. Care 38 (2016), 319–323.
84. Englert, J.A., Rogers, A.J., Metabolism, metabolomics, and nutritional support of patients with sepsis. Clin. Chest Med. 37:2 (2016), 321–331.
85. Alverdy, J.C., Krezalek, M.A., Collapse of the Microbiome, Emergence of the Pathobiome, and the Immunopathology of Sepsis. Crit. Care Med. 45:2 (2017), 337–347.
86. Wei, Y., Yang, J., Wang, J., Yang, Y., Huang, J., Gong, H., Cui, H., Chen, D., Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis. Crit. Care (London, England), 20(1), 2016, 332.
87. O'Callaghan, E.K., Anderson, S.T., Moynagh, P.N., Coogan, A.N., Long-lasting effects of sepsis on circadian rhythms in the mouse. PLoS One, 7(10), 2012.
88. Fink, M.P., Animal models of sepsis and its complications. Kidney Int. 74:8 (2008), 991–993.
89. Buras, J.A., Holzmann, B., Sitkovsky, M., Animal models of sepsis: setting the stage, Nature reviews. Drug Discov. 4:10 (2005), 854–865.
90. Seok, J., Warren, H.S., Cuenca, A.G., Mindrinos, M.N., Baker, H.V., Xu, W., Richards, D.R., McDonald-Smith, G.P., Gao, H., Hennessy, L., Finnerty, C.C., López, C.M., Honari, S., Moore, E.E., Minei, J.P., Cuschieri, J., Bankey, P.E., Johnson, J.L., Sperry, J., Nathens, A.B., Billiar, T.R., West, M.A., Jeschke, M.G., Klein, M.B., Gamelli, R.L., Gibran, N.S., Brownstein, B.H., Miller-Graziano, C., Calvano, S.E., Mason, P.H., Cobb, J.P., Rahme, L.G., Lowry, S.F., Maier, R.V., Moldawer, L.L., Herndon, D.N., Davis, R.W., Xiao, W., Tompkins, R.G., L. and to Injury, Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 110:9 (2013), 3507–3512.
91. Opal, S.M., Endotoxins and other sepsis triggers. Contrib. Nephrol. 167 (2010), 14–24.
92. Dejager, L., Pinheiro, I., Dejonckheere, E., Libert, C., Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?. Trends Microbiol. 19:4 (2011), 198–208.
93. Schäcke, H., Döcke, W.-D., Asadullah, K., Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96:1 (2002), 23–43.
94. Barnes, P.J., Adcock, I.M., Glucocorticoid resistance in inflammatory diseases. Lancet (London, England) 373:9678 (2009), 1905–1917.
95. Manenschijn, L., van den Akker, E.L., Lamberts, S.W., van Rossum, E.F., Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann. N. Y. Acad. Sci. 1179 (2009), 179–198.
96. Chrousos, G.P., Detera-Wadleigh, S.D., Karl, M., Syndromes of glucocorticoid resistance. Ann. Intern. Med. 119:11 (1993), 1113–1124.
97. Vitellius, G., Fagart, J., Delemer, B., Amazit, L., Ramos, N., Bouligand, J., Le Billan, F., Castinetti, F., Guiochon-Mantel, A., Trabado, S., Lombès, M., Three novel heterozygous point mutations of NR3C1 causing glucocorticoid resistance. Hum. Mutat. 37:8 (2016), 794–803.
98. Charmandari, E., Ichijo, T., Jubiz, W., Baid, S., Zachman, K., Chrousos, G.P., Kino, T., A novel point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression. J. Clin. Endocrinol. Metab. 93:12 (2008), 4963–4968.
99. Nicolaides, N.C., Roberts, M.L., Kino, T., Braatvedt, G., Hurt, D.E., Katsantoni, E., Sertedaki, A., Chrousos, G.P., Charmandari, E., A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities. J. Clin. Endocrinol. Metab., 99(5), 2014, 7.
100. Charmandari, E., Primary generalized glucocorticoid resistance and hypersensitivity. Horm. Res. Paediatr. 76:3 (2011), 145–155.
101. Charmandari, E., Kino, T., Chrousos, G.P., Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms. Ann. N. Y. Acad. Sci. 1024:1 (2004), 168–181.
102. Xie, Y., Meng, Y., Li, H.F.F., Hong, Y., Sun, L., Zhu, X., Yue, Y.X.X., Gao, X., Wang, S., Li, Y., Kusner, L.L., Kaminski, H.J., GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis. Eur. J. Neurol. 23:8 (2016), 1372–1379.
103. Dejager, L., Vandevyver, S., Petta, I., Libert, C., Dominance of the strongest: inflammatory cytokines versus glucocorticoids. Cytokine Growth Factor Rev. 25:1 (2014), 21–33.
104. Van Bogaert, T., De Bosscher, K., Libert, C., Crosstalk between TNF and glucocorticoid receptor signaling pathways. Cytokine Growth Factor Rev. 21:4 (2010), 275–286.
105. Barnes, P.J., Adcock, I.M., Ito, K., Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 25:3 (2005), 552–563.
106. Marwick, J.A., Adcock, I.M., Chung, K., Overcoming reduced glucocorticoid sensitivity in airway disease. Drugs 70:8 (2010), 929–948.
107. Adcock, I.M., Cosio, B., Tsaprouni, L., Barnes, P.J., Ito, K., Redox regulation of histone deacetylases and glucocorticoid-mediated inhibition of the inflammatory response. Antioxid. Redox Signal. 7:1–2 (2005), 144–152.
108. Ito, K., Lim, S., Caramori, G., Cosio, B., Chung, F.K., Adcock, I.M., Barnes, P.J., A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. 99:13 (2002), 8921–8926.
109. Duma, D., Silva-Santos, J.E.E., Assreuy, J., Inhibition of glucocorticoid receptor binding by nitric oxide in endotoxemic rats. Crit. Care Med. 32:11 (2004), 2304–2310.
110. Mercado, N., To, Y., Ito, K., Barnes, P.J., Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-δ. J. Pharmacol. Exp. Ther. 337:2 (2011), 465–470.
111. Irusen, E., Matthews, J.G., Takahashi, A., Barnes, P.J., Chung, K.F., Adcock, I.M., p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J. Allergy Clin. Immunol. 109:4 (2002), 649–657.
112. Spahn, J.D., Szefler, S.J., Surs, W., Doherty, D.E., Nimmagadda, S.R., Leung, D.Y., A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J. Immunol. (Baltimore, Md.: 1950) 157:6 (1996), 2654–2659.
113. Kam, J.C., Szefler, S.J., Surs, W., Sher, E.R., Leung, D.Y., Combination IL-2 and, IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J. Immunol. (Baltimore, Md.: 1950) 151:7 (1993), 3460–3466.
114. Tliba, O., Damera, G., Banerjee, A., Gu, S., Baidouri, H., Keslacy, S., Amrani, Y., Cytokines induce an early steroid resistance in airway smooth muscle cells: novel role of interferon regulatory factor-1. Am. J. Respir. Cell Mol. Biol. 38:4 (2008), 463–472.
115. Zijlstra, G.J., Ten Hacken, N.H., Hoffmann, R.F., van Oosterhout, A.J., Heijink, I.H., Interleukin-17A induces glucocorticoid insensitivity in human bronchial epithelial cells. Eur. Respir. J. 39:2 (2012), 439–445.
116. Li, J.J., Wang, W., Baines, K.J., Bowden, N.A., Hansbro, P.M., Gibson, P.G., Kumar, R.K., Foster, P.S., Yang, M., IL-27/IFN- (induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages. J. Immunol. (Baltimore, Md.: 1950) 185:7 (2010), 4401–4409.
117. Hakonarson, H., Halapi, E., Whelan, R., Gulcher, J., Stefansson, K., Grunstein, M.M., Association between IL-1 β/TNF- α–induced glucocorticoid-sensitive changes in multiple gene expression and altered responsiveness in airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 25:6 (2001), 761–771.
118. Rider, C.F., King, E.M., Holden, N.S., Giembycz, M.A., Newton, R., Inflammatory stimuli inhibit glucocorticoid-dependent transactivation in human pulmonary epithelial cells: rescue by long-acting beta2-adrenoceptor agonists. J. Pharmacol. Exp. Ther. 338:3 (2011), 860–869.
119. Van Bogaert, T., Vandevyver, S., Dejager, L., Van Hauwermeiren, F., Pinheiro, I., Petta, I., Engblom, D., Kleyman, A., Schütz, G., Tuckermann, J., Libert, C., Tumor necrosis factor inhibits glucocorticoid receptor function in mice: a strong signal toward lethal shock. J. Biol. Chem. 286:30 (2011), 26555–26567.
120. Pathak, S., Goldofsky, E., Vivas, E.X., Bonagura, V.R., Vambutas, A., IL-1 β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J. Immunol. (Baltimore, Md.: 1950) 186:3 (2011), 1870–1879.
121. Chambers, E.S., Nanzer, A.M., Pfeffer, P.E., Richards, D.F., Timms, P.M., Martineau, A.R., Griffiths, C.J., Corrigan, C.J., Hawrylowicz, C.M., Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: potential benefits of calcitriol. J. Allergy Clin. Immunol. 136:3 (2015), 628–6370000.
122. Leung, D.Y., Martin, R.J., Szefler, S.J., Sher, E.R., Ying, S., Kay, A.B., Hamid, Q., Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J. Exp. Med. 181:1 (1995), 33–40.
123. Ishiguro, Y., Ohkawara, T., Sakuraba, H., Yamagata, K., Hiraga, H., Yamaguchi, S., Fukuda, S., Munakata, A., Nakane, A., Nishihira, J., Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. Clin. Immunol. 120:3 (2006), 335–341.
124. Ayoub, S., Hickey, M.J., Morand, E.F., Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis, Nature clinical practice. Rheumatology 4:2 (2008), 98–105.
125. Xystrakis, E., Kusumakar, S., Boswell, S., Peek, E., Urry, Z., Richards, D.F., Adikibi, T., Pridgeon, C., Dallman, M., Loke, T.-K.K., Robinson, D.S., Barrat, F.J., O'Garra, A., Lavender, P., Lee, T.H., Corrigan, C., Hawrylowicz, C.M., Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J. Clin. Invest. 116:1 (2006), 146–155.
126. Bogaert, P., Naessens, T., Koker, D.S., Hennuy, B., Hacha, J., Smet, M., Cataldo, D., Valentin, D.E., Piette, J., Tournoy, K.G., Grooten, J., Inflammatory signatures for eosinophilic vs. neutrophilic allergic pulmonary inflammation reveal critical regulatory checkpoints. AJP: Lung Cell. Mol. Physiol., 300(5), 2011.
127. Dejager, L., Dendoncker, K., Eggermont, M., Souffriau, J., Van Hauwermeiren, F., Willart, M., Van Wonterghem, E., Naessens, T., Ballegeer, M., Vandevyver, S., Hammad, H., Lambrecht, B., De Bosscher, K., Grooten, J., Libert, C., Neutralizing TNFα restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation. Mucosal Immunol. 8:6 (2015), 1212–1225.
128. Vambutas, A., Lesser, M., Mullooly, V., Pathak, S., Zahtz, G., Rosen, L., Goldofsky, E., Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. J. Clin. Invest. 124:9 (2014), 4115–4122.
129. Matsumura, Y., Heterogeneity of glucocorticoid resistance in patients with bronchial asthma. Int. J. Biomed. Sci.: IJBS 6:3 (2010), 158–166.
130. Tantisira, K.G., Lasky-Su, J., Harada, M., Murphy, A., Litonjua, A.A., Himes, B.E., Lange, C., Lazarus, R., Sylvia, J., Klanderman, B., Duan, Q.L., Qiu, W., Hirota, T., Martinez, F.D., Mauger, D., Sorkness, C., Szefler, S., Lazarus, S.C., Lemanske, R.F., Peters, S.P., Lima, J.J., Nakamura, Y., Tamari, M., Weiss, S.T., Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365:13 (2011), 1173–1183.
131. Clark, A.R., MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids?. J. Endocrinol. 178:1 (2003), 5–12.
132. Bhavsar, P., Hew, M., Khorasani, N., Torrego, A., Barnes, P.J., Adcock, I., Chung, K.F., Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 63:9 (2008), 784–790.
133. Barnes, P.J., Ito, K., Adcock, I.M., Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet (London, England) 363:9410 (2004), 731–733.
134. Gruhn, B., Naumann, T., Gruner, D., Walther, M., Wittig, S., Becker, S., Beck, J.F., Sonnemann, J., The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. Leuk. Res. 37:10 (2013), 1200–1207.
135. Jones, C.L., Bhatla, T., Blum, R., Wang, J., Paugh, S.W., Wen, X., Bourgeois, W., Bitterman, D.S., Raetz, E.A., Morrison, D.J., Teachey, D.T., Evans, W.E., Garabedian, M.J., Carroll, W.L., Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J. Biol. Chem. 289:30 (2014), 20502–20515.
136. Sohn, K.-C.C., Jang, S., Choi, D.-K.K., Lee, Y.-S.S., Yoon, T.-J.J., Jeon, E.K., Kim, K.H., Seo, Y.-J.J., Lee, J.-H.H., Park, J.-K.K., Kim, C.D., Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells. Biochem. Biophys. Res. Commun. 356:3 (2007), 810–815.
137. Matysiak, M., Makosa, B., Walczak, A., Selmaj, K., Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex. Mult. Scler. (Houndmills, Basingstoke, England) 14:7 (2008), 919–926.
138. Farrell, R.J., Murphy, A., Long, A., Donnelly, S., Cherikuri, A., O'Toole, D., Mahmud, N., Keeling, P.W., Weir, D.G., Kelleher, D., High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118:2 (2000), 279–288.
139. Tsujimura, S., Saito, K., Nawata, M., Nakayamada, S., Tanaka, Y., Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann. Rheum. Dis. 67:3 (2008), 380–388.
140. Vedeckis, W.V., Ali, M., Allen, H.R., Regulation of glucocorticoid receptor protein and mRNA levels. Cancer Res., 49(8 Suppl), 1989.
141. Drouin, J., Trifiro, M.A., Plante, R.K., Nemer, M., Eriksson, P., Wrange, O., Glucocorticoid receptor binding to a specific DNA sequence is required for hormone-dependent repression of pro-opiomelanocortin gene transcription. Mol. Cell. Biol. 9:12 (1989), 5305–5314.
142. Govindan, M.V., Pothier, F., Leclerc, S., Palaniswami, R., Xie, B., Human glucocorticoid receptor gene promotor-homologous down regulation. J. Steroid Biochem. Mol. Biol. 40:1–3 (1991), 317–323.
143. Shaw, G., Kamen, R., A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:5 (1986), 659–667.
144. McIntyre, W.R., Samuels, H.H., Triamcinolone acetonide regulates glucocorticoid-receptor levels by decreasing the half-life of the activated nuclear-receptor form. J. Biol. Chem. 260:1 (1985), 418–427.
145. Green, T.L., Leventhal, S.M., Lim, D., Cho, K., Greenhalgh, D.G., A tri-nucleotide pattern in a 3' UTR segment affects the activity of a human glucocorticoid receptor isoform. Shock (Augusta, Ga.) 47:2 (2017), 148–157.
146. Wallace, A.D., Cidlowski, J.A., Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J. Biol. Chem. 276:46 (2001), 42714–42721.
147. Ledderose, C., Möhnle, P., Limbeck, E., Schütz, S., Weis, F., Rink, J., Briegel, J., Kreth, S., Corticosteroid resistance in sepsis is influenced by microRNA-124–induced downregulation of glucocorticoid receptor-α. Crit. Care Med. 40:10 (2012), 2745–2753.
148. Leung, D.Y., Hamid, Q., Vottero, A., Szefler, S.J., Surs, W., Minshall, E., Chrousos, G.P., Klemm, D.J., Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J. Exp. Med. 186:9 (1997), 1567–1574.
149. Hamid, Q.A., Wenzel, S.E., Hauk, P.J., Tsicopoulos, A., Wallaert, B., Lafitte, J.J., Chrousos, G.P., Szefler, S.J., Leung, D.Y., Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am. J. Respir. Crit. Care Med. 159:5 Pt 1 (1999), 1600–1604.
150. Sousa, A.R., Lane, S.J., Cidlowski, J.A., Staynov, D.Z., Lee, T.H., Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform. J. Allergy Clin. Immunol. 105:5 (2000), 943–950.
151. Christodoulopoulos, P., Leung, D.Y., Elliott, M.W., Hogg, J.C., Muro, S., Toda, M., Laberge, S., Hamid, Q.A., Increased number of glucocorticoid receptor-beta-expressing cells in the airways in fatal asthma. J. Allergy Clin. Immunol. 106:3 (2000), 479–484.
152. Goleva, E., Li, L.-B.B., Eves, P.T., Strand, M.J., Martin, R.J., Leung, D.Y., Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma. Am. J. Respir. Crit. Care Med. 173:6 (2006), 607–616.
153. Shahidi, H., Vottero, A., Stratakis, C.A., Taymans, S.E., Karl, M., Longui, C.A., Chrousos, G.P., Daughaday, W.H., Gregory, S.A., Plate, J.M., Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. Biochem. Biophys. Res. Commun. 254:3 (1999), 559–565.
154. Honda, M., Orii, F., Ayabe, T., Imai, S., Ashida, T., Obara, T., Kohgo, Y., Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 118:5 (2000), 859–866.
155. Fujishima, S.-i., Takeda, H., Kawata, S., Yamakawa, M., The relationship between the expression of the glucocorticoid receptor in biopsied colonic mucosa and the glucocorticoid responsiveness of ulcerative colitis patients. Clin. Immunol. (Orlando, Fla.) 133:2 (2009), 208–217.
156. Derijk, R.H., Schaaf, M.J., Turner, G., Datson, N.A., Vreugdenhil, E., Cidlowski, J., de Kloet, E.R., Emery, P., Sternberg, E.M., Detera-Wadleigh, S.D., A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J. Rheumatol. 28:11 (2001), 2383–2388.
157. Paugh, S.W., Bonten, E.J., Savic, D., Ramsey, L.B., Thierfelder, W.E., Gurung, P., Malireddi, R.K., Actis, M., Mayasundari, A., Min, J., Coss, D.R., Laudermilk, L.T., Panetta, J.C., McCorkle, J.R., Fan, Y., Crews, K.R., Stocco, G., Wilkinson, M.R., Ferreira, A.M., Cheng, C., Yang, W., Karol, S.E., Fernandez, C.A., Diouf, B., Smith, C., Hicks, J.K., Zanut, A., Giordanengo, A., Crona, D., Bianchi, J.J., Holmfeldt, L., Mullighan, C.G., den Boer, M.L., Pieters, R., Jeha, S., Dunwell, T.L., Latif, F., Bhojwani, D., Carroll, W.L., Pui, C.-H.H., Myers, R.M., Guy, R.K., Kanneganti, T.-D.D., Relling, M.V., Evans, W.E., NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat. Genet. 47:6 (2015), 607–614.
158. Pazdrak, K., Straub, C., Maroto, R., Stafford, S., White, W.I., Calhoun, W.J., Kurosky, A., Cytokine-induced glucocorticoid resistance from eosinophil activation: protein phosphatase 5 modulation of glucocorticoid receptor phosphorylation and signaling. J. Immunol. (Baltimore, Md.: 1950) 197:10 (2016), 3782–3791.
159. Loke, T.-K., Mallett, K.H., Ratoff, J., O'Connor, B.J., Ying, S., Meng, Q., Soh, C., Lee, T.H., Corrigan, C.J., Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients. J. Allergy Clin. Immunol. 118:2 (2006), 368–375.
160. Stanczyk, J., Ospelt, C., Gay, S., Is there a future for small molecule drugs in the treatment of rheumatic diseases?. Curr. Opin. Rheumatol. 20:3 (2008), 257–262.
161. Libert, C., Van Bladel, S., Brouckaert, P., Fiers, W., The influence of modulating substances on tumor necrosis factor and interleukin-6 levels after injection of murine tumor necrosis factor or lipopolysaccharide in mice. J. Immunother. 10:4 (1991), 227–235.
162. Geller, P., Merrill, E.R., Jawetz, E., Effects of cortisone and antibiotics on lethal action of endotoxins in mice, Proceedings of the Society for Experimental Biology and Medicine. Soc. Exp. Biol. Med. (New York, N.Y.) 86:4 (1954), 716–719.
163. Germuth, F.G., The role of adrenocortical steroids in infection, immunity and hypersensitivity. Pharmacol. Rev. 8:1 (1956), 1–24.
164. Sambhi, M.P., Weil, M.H., Udhoji, V.N., Shubin, H., Adrenocorticoids in the management of shock. Int. Anesthesiol. Clin. 2 (1964), 421–433.
165. Bertini, R., Bianchi, M., Ghezzi, P., Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J. Exp. Med. 167:5 (1988), 1708–1712.
166. Brouckaert, P., Everaerdt, B., Fiers, W., The glucocorticoid antagonist RU38486 mimics interleukin-1 in its sensitization to the lethal and interleukin-6-inducing properties of tumor necrosis factor. Eur. J. Immunol. 22:4 (1992), 981–986.
167. Lazar, G., Lazar, G., Agarwal, M.K., Modification of septic shock in mice by the antiglucocorticoid RU 38486. Circ. Shock 36:3 (1992), 180–184.
168. Kleiman, A., Hübner, S., Rodriguez Parkitna, J.M., Neumann, A., Hofer, S., Weigand, M.A., Bauer, M., Schmid, W., Schütz, G., Libert, C., Reichardt, H.M., Tuckermann, J.P., Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. FASEB J. 26:2 (2012), 722–729.
169. Vandevyver, S., Dejager, L., Van Bogaert, T., Kleyman, A., Liu, Y., Tuckermann, J., Libert, C., Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. J. Clin. Invest. 122:6 (2012), 2130–2140.
170. Al-Harbi, N.O., Imam, F., Al-Harbi, M.M., Ansari, M.A., Zoheir, K.M., Korashy, H.M., Sayed-Ahmed, M.M., Attia, S.M., Shabanah, O.A., Ahmad, S.F., Dexamethasone attenuates LPS-induced acute lung injury through inhibition of NF-κB, COX-2, and pro-inflammatory mediators. Immunol. Invest. 45:4 (2016), 349–369.
171. Xu, L., Liu, S., Guan, M., Xue, Y., Comparison of prednisolone, etoricoxib, and indomethacin in treatment of acute gouty arthritis: an open-label randomized, controlled trial. Med. Sci. Monit. 22 (2016), 810–817.
172. Yeager, M.P., Guyre, P.M., Munck, A.U., Glucocorticoid regulation of the inflammatory response to injury. Acta Anaesthesiol. Scand. 48:7 (2004), 799–813.
173. Mansart, A., Bollaert, P.-E.E., Giummelly, P., Capdeville-Atkinson, C., Atkinson, J., Effects of dexamethasone and L-canavanine on the intracellular calcium-contraction relation of the rat tail artery during septic shock, American journal of physiology. Heart Circ. Physiol., 291(3), 2006, 82.
174. Lu, Z.-Q.Q., Lu, J.-X.X., Deng, Y.-J.J., Glucocorticoids offer protection against myocardial injury in a murine model of sepsis. Int. J. Clin. Exp. Med. 8:8 (2015), 12211–12218.
175. van den Berg, J.W., van der Zee, M., de Bruin, R.W., van Holten-Neelen, C., Bastiaans, J., Nagtzaam, N.M., Ijzermans, J.N., Benner, R., Dik, W.A., Mild versus strong anti-inflammatory therapy during early sepsis in mice: a matter of life and death. Crit. Care Med. 39:6 (2011), 1275–1281.
176. Dhabhar, F.S., Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation 16:5 (2009), 300–317.
177. Prigent, H., Maxime, V., Annane, D., Clinical review: corticotherapy in sepsis. Crit. Care (London, England) 8:2 (2004), 122–129.
178. Keh, D., Sprung, C.L., Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit. Care Med., 32(11 Suppl), 2004, 33.
179. Minneci, P.C., Deans, K.J., Banks, S.M., Eichacker, P.Q., Natanson, C., Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann. Intern. Med. 141:1 (2004), 47–56.
180. Dellinger, R.P., Levy, M.M., Carlet, J.M., Bion, J., Parker, M.M., Jaeschke, R., Reinhart, K., Angus, D.C., Brun-Buisson, C., Beale, R., Calandra, T., Dhainaut, J.-F.F., Gerlach, H., Harvey, M., Marini, J.J., Marshall, J., Ranieri, M., Ramsay, G., Sevransky, J., Thompson, B.T., Townsend, S., Vender, J.S., Zimmerman, J.L., Vincent, J.-L.L., International Surviving Sepsis Campaign Guidelines Committee, American Association of Critical-Care Nurses, American College of Chest Physicians, American College of Emergency Physicians, Canadian Critical Care Society, European Society of Clinical Microbiology, Infectious Diseases, European Society of Intensive Care Medicine, European Respiratory Society, International Sepsis Forum, Japanese Association for Acute Medicine, Japanese Society of Intensive Care Medicine, Society of Critical Care Medicine, Society of Hospital Medicine, Surgical Infection Society, World Federation of Societies of Intensive, Critical Care Medicine, Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36:1 (2008), 296–327.
181. Meduri, G.U., New rationale for glucocorticoid treatment in septic shock. J. Chemother. (Florence, Italy 11:6 (1999), 541–550.
182. Annane, D., Cavaillon, J.-M.M., Corticosteroids in sepsis: from bench to bedside?. Shock (Augusta, Ga) 20:3 (2003), 197–207.
183. Salluh, J.I., Póvoa, P., Corticosteroids in severe sepsis and septic shock: a concise review. Shock (Augusta, Ga.) 1 (2017), 47–51.
184. van den Akker, E.L., Koper, J.W., Joosten, K., de Jong, F.H., Hazelzet, J.A., Lamberts, S.W., Hokken-Koelega, A.C., Glucocorticoid receptor mRNA levels are selectively decreased in neutrophils of children with sepsis. Intensive Care Med. 35:7 (2009), 1247–1254.
185. Dekelbab, B.H., Witchel, S.F., DeFranco, D.B., TNF-alpha and glucocorticoid receptor interaction in L6 muscle cells: a cooperative downregulation of myosin heavy chain. Steroids 72:9–10 (2007), 705–712.
186. Guerrero, J., Gatica, H.A.A., Rodríguez, M., Estay, R., Goecke, I.A., Septic serum induces glucocorticoid resistance and modifies the expression of glucocorticoid isoforms receptors: a prospective cohort study and in vitro experimental assay. Crit. Care (London, England), 17(3), 2013.
187. Garcia-Alvarez, M., Marik, P., Bellomo, R., Sepsis-associated hyperlactatemia. Crit. Care (London, England), 18(5), 2014, 503.
188. Suetrong, B., Walley, K.R., Lactic acidosis in sepsis: it's not all anaerobic implications for diagnosis and management. Chest 149:1 (2016), 252–261.
189. Shapiro, N.I., Howell, M.D., Talmor, D., Nathanson, L.A., Lisbon, A., Wolfe, R.E., Weiss, J.W., Serum lactate as a predictor of mortality in emergency department patients with infection. Ann. Emerg. Med. 45:5 (2005), 524–528.
190. Mizock, B.A., Falk, J.L., Lactic acidosis in critical illness. Crit. Care Med. 20:1 (1992), 80–93.
191. Galley, H.F., Oxidative stress and mitochondrial dysfunction in sepsis. Br. J. Anaesth. 107:1 (2011), 57–64.
192. Rocha, M., Herance, R., Rovira, S., Hernández-Mijares, A., Victor, V.M., Mitochondrial dysfunction and antioxidant therapy in sepsis. Infect. Disord. Drug Targets 12:2 (2012), 161–178.
193. Watanabe, Y., Singamsetty, S., Zou, B., Guo, L., Stefanovski, D., Alonso, L.C., Garcia-Ocana, A., O'Donnell, C.P., McVerry, B.J., Exogenous glucose administration impairs glucose tolerance and pancreatic insulin secretion during acute sepsis in non-diabetic mice. PLoS One, 8(6), 2013.
194. Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B., Wahli, W., Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103:11 (1999), 1489–1498.
195. Leone, T.C., Weinheimer, C.J., Kelly, D.P., A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. U. S. A. 96:13 (1999), 7473–7478.
196. Janssen, A.W., Betzel, B., Stoopen, G., Berends, F.J., Janssen, I.M., Peijnenburg, A.A., Kersten, S., The impact of PPAR (activation on whole genome gene expression in human precision cut liver slices. BMC Genomics, 16, 2015, 760.
197. Thomas, G.W., Mains, C.W., Slone, D.S., Craun, M.L., Bar-Or, D., Potential dysregulation of the pyruvate dehydrogenase complex by bacterial toxins and insulin. J. Trauma 67:3 (2009), 628–633.
198. Patel, M.S., Korotchkina, L.G., The biochemistry of the pyruvate dehydrogenase complex. Biochem. Mol. Biol. Educ. 31:1 (2003), 5–15.
199. Patel, M.S., Nemeria, N.S., Furey, W., Jordan, F., The pyruvate dehydrogenase complexes: structure-based function and regulation. J. Biol. Chem. 289:24 (2014), 16615–16623.
200. Costa, N.A., Gut, A.L., de Souza Dorna, M., Pimentel, J.A.A., Cozzolino, S.M., Azevedo, P.S., Fernandes, A.A., Zornoff, L.A., de Paiva, S.A., Minicucci, M.F., Serum thiamine concentration and oxidative stress as predictors of mortality in patients with septic shock. J. Crit. Care 29:2 (2014), 249–252.
201. Ratman, D., Mylka, V., Bougarne, N., Pawlak, M., Caron, S., Hennuyer, N., Paumelle, R., De Cauwer, L., Thommis, J., Rider, M.H., Libert, C., Lievens, S., Tavernier, J., Staels, B., De Bosscher, K., Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARα. Nucleic Acids Res. 44:22 (2016), 10539–10553.
202. Garrabou, G., Morén, C., López, S., Tobías, E., Cardellach, F., Miró, O., Casademont, J., The effects of sepsis on mitochondria. J. Infect Dis. 205:3 (2012), 392–400.
203. Lin, Z.y., Xu, P.b., Yan, S.k., Meng, H.b., Yang, G.j., Dai, W.x., Liu, X.r., Li, J.b., Deng, X.m., Zhang, W.d., A metabonomic approach to early prognostic evaluation of experimental sepsis by 1H NMR and pattern recognition. NMR Biomed. 22:6 (2009), 601–608.
204. Liu, Z., Yin, P., Amathieu, R., Savarin, P., Xu, G., Application of LC-MS-based metabolomics method in differentiating septic survivors from non-survivors. Anal. Bioanal. Chem. 408:27 (2016), 7641–7649.
205. Vary, T.C., Sepsis-induced alterations in pyruvate dehydrogenase complex activity in rat skeletal muscle: effects on plasma lactate. Shock (Augusta, Ga.) 6:2 (1996), 89–94.
206. Alamdari, N., Constantin-Teodosiu, D., Murton, A.J., Gardiner, S.M., Bennett, T., Layfield, R., Greenhaff, P.L., Temporal changes in the involvement of pyruvate dehydrogenase complex in muscle lactate accumulation during lipopolysaccharide infusion in rats. J. Physiol. 586:6 (2008), 1767–1775.
207. Adeva-Andany, M.M., Perez-Felpete, N., Fernandez-Fernandez, C., Donapetry-Garcia, C., Pazos-Garcia, C., Liver glucose metabolism in humans. Biosci. Rep., 36(6), 2016.
208. Chichelnitskiy, E., Vegiopoulos, A., Berriel Diaz, M., Ziegler, A., Kleiman, A., Rauch, A., Tuckermann, J., Herzig, S., In vivo phosphoenolpyruvate carboxykinase promoter mapping identifies disrupted hormonal synergism as a target of inflammation during sepsis in mice. Hepatology (Baltimore, Md.) 50:6 (2009), 1963–1971.
209. Stafford, J.M., Wilkinson, J.C., Beechem, J.M., Accessory factors facilitate the binding of glucocorticoid receptor to the phosphoenolpyruvate carboxykinase gene promoter. J. Biol. Chem. 43 (2001), 39885–39891.
210. Nader, N., Ng, S.S., Wang, Y., Abel, B.S., Chrousos, G.P., Kino, T., Liver x receptors regulate the transcriptional activity of the glucocorticoid receptor: implications for the carbohydrate metabolism. PLoS One, 7(3), 2012.
211. Myhre, A.E., Agren, J., Dahle, M.K., Tamburstuen, M.V., Lyngstadaas, S.P.P., Collins, A.J., Foster, S.J., Thiemermann, C., Aasen, A.O., Wang, J.E., Liver X receptor is a key regulator of cytokine release in human monocytes. Shock (Augusta, Ga.) 29:4 (2008), 468–474.
212. Joseph, S.B., Bradley, M.N., Castrillo, A., Bruhn, K.W., Mak, P.A., Pei, L., Hogenesch, J., O'Connell, R.M., Cheng, G., Saez, E., Miller, J.F., Tontonoz, P., LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119:2 (2004), 299–309.
213. Vanwijngaerden, Y.-M.M., Wauters, J., Langouche, L., Vander Perre, S., Liddle, C., Coulter, S., Vanderborght, S., Roskams, T., Wilmer, A., Van den Berghe, G., Mesotten, D., Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology (Baltimore, Md.) 54:5 (2011), 1741–1752.
214. Kim, P.K., Chen, J., Andrejko, K.M., Deutschman, C.S., Intraabdominal sepsis down-regulates transcription of sodium taurocholate cotransporter and multidrug resistance-associated protein in rats. Shock (Augusta, Ga.) 14:2 (2000), 176–181.
215. Moseley, R.H., Wang, W., Takeda, H., Lown, K., Shick, L., Ananthanarayanan, M., Suchy, F.J., Effect of endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. Am. J. Physiol., 271(1 Pt 1), 1996, 46.
216. Rose, A.J., Berriel Díaz, M., Reimann, A., Klement, J., Walcher, T., Krones-Herzig, A., Strobel, O., Werner, J., Peters, A., Kleyman, A., Tuckermann, J.P., Vegiopoulos, A., Herzig, S., Molecular control of systemic bile acid homeostasis by the liver glucocorticoid receptor. Cell Metab. 14:1 (2011), 123–130.